Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ANOC 001

Next Previous
Drug Profile

ANOC 001

Alternative Names: ANOC-001; KRAS-G12V targeting TCR-T cell therapy

Latest Information Update: 26 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anocca
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Adenocarcinoma

Most Recent Events

  • 18 Aug 2025 Phase-I clinical trials in Adenocarcinoma (Late-stage disease) in Sweden, Germany, Netherlands, Denmark (Parenteral)
  • 03 Jul 2025 Phase-I/II clinical trials in Adenocarcinoma (Late-stage disease, Metastatic disease) in Germany, Netherlands, Denmark, Sweden (IV) (NCT07145450)
  • 17 Mar 2025 Anocca plans a phase I/II VIDAR-1 multi-asset umbrella trial for ANOC 001 in Adenocarcinoma (Late-stage disease) (Parenteral) in Sweden, Denmark, Germany and Netherlands in second quarter of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top